Search
+
    SEARCHED FOR:

    IPO AVOIDANCE

    IPO Analysis: Emcure has better-listed pharma alternatives

    Emcure Pharma, with its strong presence in gynaecology and HIV therapeutic areas, secured significant investments from anchor investors like HDFC Mutual Fund and ICICI Prudential Mutual Fund, showcasing immense market confidence in its upcoming IPO.

    Allied Blenders IPO: Check subscription on last day, GMP and other details

    The IPO of Allied Blenders and Distillers was subscribed 23.49 times on its third and final day. NIIs show strong interest with 32 times subscription, followed by retail investors at 4.42 times. The QIB portion of the issue was booked 50 times. The IPO combines a Rs 1,000 crore fresh equity sale and OFS of 1.77 crore shares, allowing promoters Bina Kishore Chhabria and Resham Chhabria Jeetendra to reduce their stakes.

    Allied Blenders and Distillers IPO subscribed 1.51 times on Day 2. Check subscription, GMP and other details

    ABDL's IPO involves a fresh equity sale of Rs 1,000 crore and an offer for sale (OFS) of 1.77 crore shares by promoters Bina Kishore Chhabria and Resham Chhabria Jeetendra. Funds raised will repay borrowings and fund corporate needs. The company's shares are trading with a GMP of Rs 87.

    Allied Blenders and Distillers IPO opens for subscription. Should you bid?

    Allied Blenders and Distillers IPO, featuring Officer's Choice whiskey, will open for subscription with a price band of Rs 267-281 per share. Promoters will offload part of their stakes, and analysts caution against investing due to high valuation and financial risks.

    Allied Blenders and Distillers IPO booked 51% on Day 1. Check GMP and other details

    Allied Blenders & Distillers IPO saw 51% subscription with promoters planning stake sale. Revenue grew 9% year-on-year to Rs 5,915 crore. ICICI Securities, Nuvama Wealth Management, and ITI Capital are the book running lead managers for the IPO.

    Markets should double in next four-five years: Milind Karmarkar

    Maybe we will look at it at that point in time, but right now we miss getting into it early, but as of now we do not want to buy it.

    The Economic Times
    BACK TO TOP